3-氨基-4-甲基苯磺酰胺 | 6274-28-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氨基-4-甲基苯磺酰胺
• 中文别名: 3-氨基-4-甲基苯磺胺
• 英文名称: 3-amino-4-methylbenzenesulfonamide
• 英文别名: 5-Sulfamoyl-2-methyl-anilin
• CAS: 6274-28-8
• 化学式: C₇H₁₀N₂O₂S
• mdl: MFCD00188937
• 分子量: 186.235
• InChiKey: HCZDHXMDYWZPPN-UHFFFAOYSA-N

物化性质

• 熔点：
  176 °C
• 沸点：
  411.2±55.0 °C(Predicted)
• 密度：
  1.359±0.06 g/cm3(Predicted)
• 溶解度：
  0.01 M

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  94.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2935009090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Amino-4-methylbenzenesulfonamide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Amino-4-methylbenzenesulfonamide
CAS number: 6274-28-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H10N2O2S
Molecular weight: 186.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氨基-4-甲基苯磺酰胺 在 N-碘代丁二酰亚胺 、 sodium nitrite 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以65%的产率得到3-iodo-4-methylbenzenesulfonamide
  参考文献：
  名称：

  通过亚硝酸钠和N-卤代琥珀酰亚胺将芳胺直接转化为卤代芳烃

  摘要：

  描述了一种在室温下在无金属和无酸条件下，通过与亚硝酸钠（NaNO 2）和N-卤代琥珀酰亚胺（NXS）在DMF中反应，将芳基胺转化为芳基卤化物的一锅通用方法。建议与桑德迈尔反应互补的这一新方案涉及原位产生的硝基卤化物引起芳基胺的亚硝化反应，形成重氮中间体，将其卤化以提供芳基卤化物。

  DOI：

  10.1002/chem.201803347
• 作为产物：
  描述：

  2-甲基苯胺 盐酸盐 在 chlorosulphuric acid 作用下， 生成 3-氨基-4-甲基苯磺酰胺
  参考文献：
  名称：

  Process for preparing sulfonamides

  摘要：

  公开号：

  US02441671A1

文献信息

• Uncovering an allosteric mode of action for a selective inhibitor of human Bloom syndrome protein
  作者：Xiangrong Chen、Yusuf I Ali、Charlotte EL Fisher、Raquel Arribas-Bosacoma、Mohan B Rajasekaran、Gareth Williams、Sarah Walker、Jessica R Booth、Jessica JR Hudson、S Mark Roe、Laurence H Pearl、Simon E Ward、Frances MG Pearl、Antony W Oliver

  DOI：10.7554/elife.65339

  日期：——

  syndrome protein) is a RECQ-family helicase involved in the dissolution of complex DNA structures and repair intermediates. Synthetic lethality analysis implicates BLM as a promising target in a range of cancers with defects in the DNA damage response; however, selective small molecule inhibitors of defined mechanism are currently lacking. Here, we identify and characterise a specific inhibitor of BLM’s

  BLM（布卢姆综合征蛋白）是一种 RECQ 家族解旋酶，参与复杂 DNA 结构的溶解和修复中间体。综合致死率分析表明 BLM 是一系列 DNA 损伤反应缺陷癌症的有希望的靶标；然而，目前缺乏具有明确机制的选择性小分子抑制剂。在这里，我们通过 DNA 结合易位中间体的变构捕获，鉴定并表征了 BLM ATP 酶偶联 DNA 解旋酶活性的特异性抑制剂。 BLM-DNA-ADP-抑制剂复合物的晶体结构识别出迄今为止未知的域间界面，其打开和关闭对于单链DNA的易位是不可或缺的，并且为药物发现提供了高度选择性的口袋。与其他 RECQ 解旋酶结构的比较提供了通过 BLM 进行霍利迪连接的分支迁移的模型。
• Synthesis of Aromatic Aminosulfonic Acid Nitroamides
  作者：Kazimierz Minksztym

  DOI：10.1055/s-2007-983715

  日期：2007.6

  Nitration of aromatic aminosulfonic acid primary amides to furnish the corresponding sulfononitroamides has been described for the first time. The conditions of nitration applied ensure chemoselective mononitration and prevent decomposition of the product. Synthesis of dabsyl nitroamide sodium salt, as a potential β-amyloid aggregation inhibitor is also reported.

  首次报道了芳氨基磺酸一级酰胺的硝化反应，生成相应的磺酰硝酰胺。所采用的硝化条件确保了化学选择性的单硝化并防止了产物的分解。同时，还报道了作为一种潜在β-淀粉样蛋白聚集抑制剂的dabsyl硝酰胺钠盐的合成。
• [EN] METHODS FOR INHIBITING NECROPTOSIS<br/>[FR] MÉTHODES POUR INHIBER LA NÉCROPTOSE
  申请人：CATALYST THERAPEUTICS PTY LTD

  公开号：WO2015172203A1

  公开（公告）日：2015-11-19

  The present invention relates to methods for inhibiting necroptosis; screening methods for identifying compounds which inhibit necroptosis; and compounds for the inhibition of necroptosis, which may be useful in the treatment of conditions associated with deregulated necroptosis.

  本发明涉及抑制坏死程序的方法；用于识别抑制坏死程序的化合物的筛选方法；以及用于抑制坏死程序的化合物，可能在治疗与失调坏死程序相关的疾病中有用。
• [EN] PYRRAZOLO-PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRRAZOLO-PYRIMIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005123738A1

  公开（公告）日：2005-12-29

  The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5 and p are as defined in the description and claims as well as to pharmaceutically acceptable salts thereof per se and as pharmaceutically active substances, their manufacture, medicaments based on a compound in accordance with the invention and their production, as well as the use of the compounds in accordance with the invention in the control or prevention of illnesses of the aforementioned kind, and, respectively, for the production of corresponding medicaments.

  该发明涉及公式（I）中R1、R2、R3、R4、R5和p的化合物，其中这些参数在说明和权利要求中有定义，以及其药学上可接受的盐本身和作为药用活性物质，其制备方法，基于与该发明相符合的化合物的药物，以及它们的生产，以及在控制或预防上述疾病方面使用与该发明相符合的化合物，以及分别用于生产相应的药物。
• Non-nucleoside reverse transcriptase inhibitors
  申请人：Mirzadegan Taraneh

  公开号：US20070088053A1

  公开（公告）日：2007-04-19

  The present invention provides for compounds useful for treating an HIV-1 infection, or preventing an HIV-1 infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1-R4 and Ar are as herein defined. Also disclosed in the present invention are methods of treating an HIV-1 infection with compounds defined herein and pharmaceutical compositions containing said compounds.

  本发明提供了用于治疗HIV-1感染、预防HIV-1感染、治疗AIDS或ARC的化合物。本发明的化合物具有以下式I的结构，其中R1-R4和Ar如本文所定义。本发明还公开了使用本文所定义的化合物治疗HIV-1感染的方法以及含有这些化合物的药物组合物。